FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

Melanotan I

Afamelanotide / Scenesse / MT-1 / NDP-alpha-MSH

Beauty & Skincare

Melanotan I (afamelanotide) is a synthetic 13-amino acid linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) that selectively agonizes the melanocortin-1 receptor (MC1R) to stimulate eumelanin production in the skin. It is FDA-approved under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike its counterpart Melanotan II, afamelanotide has a more selective receptor profile with significantly fewer systemic side effects.

作用机制

Synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). Binds melanocortin-1 receptor (MC1R) on melanocytes, stimulating eumelanin production and distribution. Produces gradual, UV-independent tanning. Does not significantly affect sexual function (unlike MT-II).

研究协议

仅供研究使用,非医疗建议。

Research protocols use 0.5-1mg daily via subcutaneous injection for 10-14 days as a loading phase, then 0.5mg 2-3 times weekly for maintenance. Some UV exposure enhances tanning response.

研究笔记

Clinical Research Status

Afamelanotide received FDA approval in October 2019 and EMA approval in 2014 for erythropoietic protoporphyria, making it one of the few melanocortin peptides to achieve regulatory approval. Additional clinical trials have investigated its potential in vitiligo (to enhance repigmentation when combined with UV therapy), polymorphous light eruption, and solar urticaria. Research into its photoprotective properties for skin cancer prevention in organ transplant recipients has also been explored in Phase II studies.

Key Published Findings

The pivotal Phase III trial (CUV039) demonstrated that afamelanotide significantly increased pain-free time in sunlight for EPP patients compared to placebo, with a median increase of approximately 70 hours over a 6-month period. Vitiligo studies show enhanced and accelerated repigmentation when afamelanotide implants are combined with narrowband UVB phototherapy compared to phototherapy alone. Mechanistic research confirms that MC1R activation by afamelanotide triggers eumelanin synthesis through the cAMP/PKA pathway without requiring UV exposure.

Safety Profile

The most common adverse effects include nausea, headache, and darkening of pre-existing nevi (moles), with injection site reactions at the implant location. Unlike Melanotan II, afamelanotide does not typically cause facial flushing, nausea at therapeutic doses, or sexual side effects due to its selectivity for MC1R over MC3R/MC4R. Long-term surveillance data spanning over a decade of use has not identified increased melanoma risk, though regular dermatological monitoring is recommended.

Comparison to Related Compounds

Melanotan I is a linear peptide with high MC1R selectivity, while Melanotan II is a cyclic heptapeptide with broad activity across MC1R, MC3R, MC4R, and MC5R receptors, explaining MT-II's wider side effect profile including appetite suppression and sexual effects. Afamelanotide produces more gradual, natural-appearing tanning compared to the rapid but sometimes uneven pigmentation seen with Melanotan II. The FDA-approved implant formulation provides sustained release over approximately 60 days, whereas MT-II requires frequent subcutaneous injections.

Community Observations

Users seeking cosmetic tanning generally prefer Melanotan II for its faster onset and additional effects, while those specifically interested in photoprotection without sexual side effects may prefer Melanotan I. The FDA-approved implant form (Scenesse) is extremely expensive and limited to EPP patients, leading some users to source research-grade afamelanotide powder for self-administration. Community reports suggest more natural and even tanning compared to MT-II, but with a slower onset typically requiring 2-4 weeks before visible pigmentation changes.

半衰期

~30 minutes

复溶

Bacteriostatic water (BAC)

存储

冻干

Refrigerate 2-8C up to 24 months. Protect from light.

复溶后

Refrigerate 2-8C. Use within 30 days.

美国法律状态

FDA-approved for EPP only (Rx - Scenesse)

又称作

AfamelanotideScenesseMT-1NDP-alpha-MSH

常见问题

什么是 Melanotan I?

Melanotan I (afamelanotide) is a synthetic 13-amino acid linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) that selectively agonizes the melanocortin-1 receptor (MC1R) to stimulate eumelanin production in the skin. It is FDA-approved under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike its counterpart Melanotan II, afamelanotide has a more selective receptor profile with significantly fewer systemic side effects.

Melanotan I 如何起作用?

Synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). Binds melanocortin-1 receptor (MC1R) on melanocytes, stimulating eumelanin production and distribution. Produces gradual, UV-independent tanning. Does not significantly affect sexual function (unlike MT-II).

Melanotan I 在美国的监管状态是什么?

FDA-approved for EPP only (Rx - Scenesse)

Melanotan I 的半衰期是多少?

~30 minutes

Melanotan I 还有哪些名称?

Afamelanotide, Scenesse, MT-1, NDP-alpha-MSH

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明